drugset / Trial / NCT02022917
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Phase 2
Completed
22 enrolled
Chang Gung Memorial Hospital
Asian Gynecologic Oncology Group · collabHoffmann-La Roche · collabTaiwanese Gynecolgic Oncology Group · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the feasibility of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC or IV ovarian, tubal, and peritoneal cancer.
Timeline
- Start
- 2014-03
- Primary completion
- 2021-01
- Completion
- 2021-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |